Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.58 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.58 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.58 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.58 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29508931 | 1.00 | GRIN2D (0.58) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4437674 | 0.98 | GRIN2D (0.57) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL27517144 | 0.98 | GRIN2D (0.57) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29509151 | 0.98 | GRIN2D (0.57) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL14335129 | 0.85 | GRIN2D (0.55) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29445436 | 0.83 | CYP1A2 (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL14782171 | 0.83 | GRIN2D (0.58) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1551043 | 0.83 | CYP1A2 (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8415184 | 0.83 | EPHX2 (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4865013 | 0.83 | GRIN2D (0.54) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104918940-B | Purine inhibitors of human phosphatidylinositol 3-kinase | 默沙东公司 | 2017-03-08 | — | — | CN | claimed |
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3994132-A1 | TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114302878-A | Tyrosine kinase non-receptor 1(TNK1) inhibitors and uses thereof | 大日本住友制药肿瘤公司 | 2022-04-08 | — | — | CN | disclosed |
| WO-2021003417-A1 | TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-20210000825-A1 | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | SUMITOMO PHARMA ONCOLOGY, INC. | 2021-01-07 | — | — | US | disclosed |
| WO-2021003417-A1 | TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-20210000825-A1 | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | SUMITOMO PHARMA ONCOLOGY, INC. | 2021-01-07 | — | — | US | disclosed |
| US-10344017-B2 | Pyrrolcarboxamide derivatives for the inhibition of ERK5 | CANCER RESEARCH TECH LTD (GB) | 2019-07-09 | — | — | US | disclosed |
| US-20180170911-A1 | PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHIBITION OF ERK5 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| EP-3194390-A1 | PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHBITION OF ERK5 | Cancer Research Technology Ltd (GB) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016042341-A1 | PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHBITION OF ERK5 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-03-24 | — | — | WO | disclosed |
| US-7361662-B2 | Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same | LES LABORATOIRES SERVIER (FR) | 2008-04-22 | — | — | US | disclosed |
| CN-1330650-C | Pyridopyrimidinone compounds, process for their preparation and medicaments containing them | SERVIER LAB (FR) | 2007-08-08 | — | — | CN | disclosed |
| EP-1560826-B1 | PYRIDOPYRIMIDINONE COMPOUNDS, METHOD FOR PRODUCTION THEREOF AND MEDICAMENTS COMPRISING THE SAME | SERVIER LAB (FR) | 2006-04-12 | — | — | EP | disclosed |
| US-20050288311-A1 | Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same | LES LABORATOIERS SERVIER (FR) | 2005-12-29 | — | — | US | disclosed |
| CN-1711260-A | Pyridopyrimidinone compounds, process for their preparation and medicaments containing them | SERVIER LAB (FR) | 2005-12-21 | — | — | CN | disclosed |
| EP-1560826-A1 | PYRIDOPYRIMIDINONE COMPOUNDS, METHOD FOR PRODUCTION THEREOF AND MEDICAMENTS COMPRISING THE SAME | Les Laboratoires Servier (FR) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004043956-A1 | PYRIDOPYRIMIDINONE COMPOUNDS, METHOD FOR PRODUCTION THEREOF AND MEDICAMENTS COMPRISING THE SAME | LES LABORATOIRES SERVIER (FR) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000825-A1 | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | TNK1, TNNI3K, TYK2 | GRIN2D 2440/4885GRIN3B 1515/4885GRIN1 501/4885 |
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | TNK1, TNNI3K, TYK2 | GRIN2D 2440/4885GRIN3B 1515/4885GRIN1 501/4885 |
| US-20180170911-A1 | PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHIBITION OF ERK5 | MAPKAPK5, MAP3K5, MAPK15 | GRIN2D 4398/4885GRIN3B 3664/4885GRIN1 1605/4885 |
| US-20050288311-A1 | Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same | MAP4K2, PLK2, MAP4K3 | GRIN2D 1759/4885GRIN3B 1675/4885GRIN1 1201/4885 |
| US-10344017-B2 | Pyrrolcarboxamide derivatives for the inhibition of ERK5 | MAPKAPK5, MAP3K5, MAPK15 | GRIN2D 4398/4885GRIN3B 3664/4885GRIN1 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.